Kristen Fortney - Apr 17, 2024 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Chief Executive Officer, Director
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Stock symbol
BIOA
Transactions as of
Apr 17, 2024
Transactions value $
$0
Form type
4
Date filed
9/27/2024, 04:25 PM
Next filing
Sep 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOA Stock Option (Right to Buy) Award $0 +425K $0.00 425K Sep 25, 2024 Common Stock 425K $18.00 Direct F1
transaction BIOA Stock Option (Right to Buy) Award $0 +708K $0.00 708K Apr 17, 2024 Common Stock 708K $8.39 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 25, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a).
F3 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.